Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- (-) Safety monitoring and information (97)
- Advertising (273)
- COVID-19 (163)
- Legislation (93)
- Compliance and enforcement (66)
- Vaping hub (53)
- Manufacturing (52)
- Labelling and packaging (35)
- Scheduling (national classification system) (27)
- Import and export (26)
- Medicinal cannabis hub (25)
- Sunscreens (16)
- Shortages and supply disruptions (14)
- Weight loss products (14)
- Committees and advisory bodies (9)
- Cosmetics (5)
- Unique Device Identification (UDI) hub (4)
- Clinical trials (3)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
97 result(s) found, displaying 26 to 50
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Media releasesThe TGA has facilitated the seizure of millions of counterfeit and illegal therapeutic goods as part of a global initiative targeting illegal trade.
-
News articlesFollowing a number of stakeholder queries, the TGA is providing an updated statement on the PFAS ban. The original statement was published on 27 June 2025.
-
News articlesAn update about expected increases in the number of medical device incident reports reported to the TGA
-
Media releasesAustralians who rely on medical devices will benefit from new measures introduced by the Australian Government to enhance the identification and management of device-related safety concerns.
-
News articlesMedical devices, including components in the device, primary packaging, instructions for use, and spare parts, will not be affected by the PFAS ban.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesInformation about the indications for the individual products and how to avoid administration errors.
-
Safety updatesNew warnings added of risks during anaesthesia or deep sedation.
-
Media releasesThe Therapeutic Goods Administration has commenced proceedings in the Federal Court of Australia against Philips Electronics Australia Limited (PEAL) for the alleged unlawful supply of medical devices that did not meet Australian safety and performance requirements.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesRisk of Guillain-Barre syndrome added to Product Information.
-
Safety updatesUpdated illustrations clarify how to use measuring syringe for oral solutions.
-
BlogLike all goods available in Australia, therapeutic goods can sometimes experience problems. When this happens, we decide if a ‘market action’ is needed. A market action aims to correct the problem. There are four types of market actions you should be aware of.
-
BlogComplementary medicines are therapeutic goods that are often derived from traditional medicine practices. They can usually be purchased from supermarkets, health stores and pharmacies without seeing a doctor or pharmacist.
However, just because a medicine is available without a prescription, or claims to be ‘natural’ or ‘healthy’, doesn’t mean it’s safe for you. -
BlogWhile we encourage health practitioners to prescribe approved therapeutic goods where possible, unapproved therapeutic goods can be accessed in limited circumstances.
In making these joint decisions to use an unapproved therapeutic good, your doctor is required to inform you of the potential benefits and risks. -
News articlesUpdated information for nitrosamine impurities in medicines consistent with recent EMA updated information.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesUpdates further highlight potential risks of mood-related changes and sexual disorders.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesMore prominent warnings are being added to the Product Information (PI) and Consumer Medicine Information (CMI) for all oral and injectable (systemic) fluoroquinolones to strengthen existing warnings about serious side effects
-
Safety updatesThere may be an increased risk of neurodevelopmental disorders in children born to men who have taken sodium valproate in the 3 months before conception.
-
News articlesFollowing a request from the sponsor to reconsider their decision, the TGA has confirmed the initial decision to not register the medicine on the basis that the safety and efficacy of the medicine were not satisfactorily established.
-
News articlesWe are updating information for nitrosamine impurities and other nitroso-structure impurities in medicines including acceptable intakes (AI)
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.